Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma

被引:12
作者
Kanai, Tomoya [1 ]
Ito, Zensho [1 ]
Oji, Yusuke [2 ]
Suka, Machi [3 ]
Nishida, Sumiyuki [4 ]
Takakura, Kazuki [1 ]
Kajihara, Mikio [1 ]
Saruta, Masayuki [5 ]
Fujioka, Shuichi [6 ]
Misawa, Takeyuki [6 ]
Akiba, Tadashi [6 ]
Yanagisawa, Hiroyuki [3 ]
Shimodaira, Shigetaka [7 ]
Okamoto, Masato [8 ]
Sugiyama, Haruo [9 ]
Koido, Shigeo [1 ,10 ]
机构
[1] Jikei Univ, Sch Med, Kashiwa Hosp, Div Gastroenterol & Hepatol,Dept Internal Med, 163-1 Kashiwa Shita, Kashiwa, Chiba 2778567, Japan
[2] Osaka Univ, Grad Sch Med, Dept Funct Diagnost Sci, Suita, Osaka 5650871, Japan
[3] Jikei Univ, Sch Med, Dept Publ Hlth & Environm Med, Tokyo 1058571, Japan
[4] Osaka Univ, Grad Sch Med, Dept Resp Med & Clin Immunol, Suita, Osaka 5650871, Japan
[5] Jikei Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo 1058571, Japan
[6] Jikei Univ, Sch Med, Kashiwa Hosp, Dept Surg, Kashiwa, Chiba 2778567, Japan
[7] Kanazawa Med Univ, Dept Regenerat Med, Uchinada, Ishikawa 9200293, Japan
[8] Osaka Univ, Grad Sch Med, Dept Adv Immunotherapeut, Suita, Osaka 5650871, Japan
[9] Osaka Univ, Grad Sch Med, Dept Canc Immunol, Suita, Osaka 5650871, Japan
[10] Jikei Univ, Sch Med, Inst Clin Med & Res, Kashiwa, Chiba 2778567, Japan
关键词
Wilms' tumor 1; pancreatic cancer; prognosis; GENE WT1; 5-YEAR SURVIVORS; POOR-PROGNOSIS; CANCER-CELLS; PROTEIN; GEMCITABINE; THERAPY; OVEREXPRESSION; CARCINOMA; LEUKEMIA;
D O I
10.3892/ol.2018.8961
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The only current curative treatment for patients with pancreatic ductal adenocarcinoma (PDA) is surgical resection, and certain patients still succumb to disease shortly after complete surgical resection. Wilms' tumor 1 (WT1) serves an oncogenic role in various types of tumors; therefore, in the present study, WT1 protein expression in patients with PDA was analyzed and the association with overall survival (OS) and disease-free survival (DFS) time in patients with PDA was assessed following surgical resection. A total of 50 consecutive patients with PDA who received surgical resection between January 2005 and December 2015 at the Jikei University Kashiwa Hospital (Kashiwa, Chiba, Japan) were enrolled. WT1 protein expression in PDA tissue was measured using immunohistochemical staining. Furthermore, laboratory parameters were measured within 2 weeks of surgery, and systemic inflammatory response markers were evaluated. WT1 protein expression was detected in the nucleus and cytoplasm of all PDA cells and in tumor vessels. WT1 exhibited weak staining in the nuclei of all PDA cells; however, the cytoplasmic expression of WT1 levels was classified into four groups: Negative (n=0), weak (n=19), moderate (n=23) and strong (n=8). In patients with PDA, it was demonstrated that the OS and DFS times of patients with weak cytoplasmic WT1 expression were significantly prolonged compared with those of patients with moderate-to-strong cytoplasmic WT1 expression, as determined by log-rank test (P=0.0005 and P=0.0001, respectively). Furthermore, an association between the density of WT1-expressing tumor vessels and worse OS/DFS times was detected. Multivariate analysis also indicated a significant association between the overexpression of WT1 in PDA tissue and worse OS/DFS times. To the best of our knowledge, the present study is the first to demonstrate that moderate-to-strong overexpression of WT1 in the cytoplasm of PDA cells is significantly associated with worse OS/DFS times. Therefore, overexpression of WT1 in the cytoplasm of PDA cells may impact the recurrence and prognosis of patients with PDA following surgical resection. The results further support the development of WT1-targeted therapies to prolong survival in all patients with PDA.
引用
收藏
页码:2682 / 2692
页数:11
相关论文
共 62 条
  • [1] Long-Term Survival (5-20 Years) After Pancreatectomy for Pancreatic Ductal Adenocarcinoma A Series of 30 Patients Collected From 3 Institutions
    Adham, Mustapha
    Jaeck, Daniel
    Le Borgne, Joel
    Oussoultzouglou, Elie
    Chenard-Neu, Marie-Pierre
    Mosnier, Jean-Francois
    Scoazec, Jean-Yves
    Mornex, Francoise
    Partensky, Christian
    [J]. PANCREAS, 2008, 37 (04) : 352 - 357
  • [2] The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging
    Amin, Mahul B.
    Greene, Frederick L.
    Edge, Stephen B.
    Compton, Carolyn C.
    Gershenwald, Jeffrey E.
    Brookland, Robert K.
    Meyer, Laura
    Gress, Donna M.
    Byrd, David R.
    Winchester, David P.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) : 93 - 99
  • [3] Cytoplasmic overexpression of WT-1 in gastrointestinal stromal tumor and other soft tissue tumors
    Bing, Zhanyong
    Pasha, Theresa L.
    Zhang, Paul J.
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2008, 16 (04) : 316 - 321
  • [4] ISOLATION AND CHARACTERIZATION OF A ZINC FINGER POLYPEPTIDE GENE AT THE HUMAN CHROMOSOME-11 WILMS TUMOR LOCUS
    CALL, KM
    GLASER, T
    ITO, CY
    BUCKLER, AJ
    PELLETIER, J
    HABER, DA
    ROSE, EA
    KRAL, A
    YEGER, H
    LEWIS, WH
    JONES, C
    HOUSMAN, DE
    [J]. CELL, 1990, 60 (03) : 509 - 520
  • [5] Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
    Chantrill, Lorraine A.
    Nagrial, Adnan M.
    Watson, Clare
    Johns, Amber L.
    Martyn-Smith, Mona
    Simpson, Skye
    Mead, Scott
    Jones, Marc D.
    Samra, Jaswinder S.
    Gill, Anthony J.
    Watson, Nicole
    Chin, Venessa T.
    Humphris, Jeremy L.
    Chou, Angela
    Brown, Belinda
    Morey, Adrienne
    Pajic, Marina
    Grimmond, Sean M.
    Chang, David K.
    Thomas, David
    Sebastian, Lucille
    Sjoquist, Katrin
    Yip, Sonia
    Pavlakis, Nick
    Asghari, Ray
    Harvey, Sandra
    Grimison, Peter
    Simes, John
    Biankin, Andrew V.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (09) : 2029 - 2037
  • [6] The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
    Cheever, Martin A.
    Allison, James P.
    Ferris, Andrea S.
    Finn, Olivera J.
    Hastings, Benjamin M.
    Hecht, Toby T.
    Mellman, Ira
    Prindiville, Sheila A.
    Viner, Jaye L.
    Weiner, Louis M.
    Matrisian, Lynn M.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5323 - 5337
  • [7] Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors
    Cleary, SP
    Gryfe, R
    Guindi, M
    Greig, P
    Smith, L
    Mackenzie, R
    Strasberg, S
    Hanna, S
    Taylor, B
    Langer, B
    Gallinger, S
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (05) : 722 - 731
  • [8] FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
  • [9] Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis
    Gu, Liangyou
    Li, Hongzhao
    Chen, Luyao
    Ma, Xin
    Li, Xintao
    Gao, Yu
    Zhang, Yu
    Xie, Yongpeng
    Zhang, Xu
    [J]. ONCOTARGET, 2016, 7 (22) : 31926 - 31942
  • [10] Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic Collaborative Study
    Hsu, Charles C.
    Herman, Joseph M.
    Corsini, Michele M.
    Winter, Jordan M.
    Callister, Matthew D.
    Haddock, Michael G.
    Cameron, John L.
    Pawlik, Timothy M.
    Schulick, Richard D.
    Wolfgang, Christopher L.
    Laheru, Daniel A.
    Farnell, Michael B.
    Swartz, Michael J.
    Gunderson, Leonard L.
    Miller, Robert C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (04) : 981 - 990